BCRX - BioCryst Pharmaceuticals, Inc.
3.6000 0.00 (0.00%)
After hours: 5:00PM EDT
| Previous Close | 3.6000 |
| Open | 3.5600 |
| Bid | 3.6000 x 1300 |
| Ask | 3.6200 x 900 |
| Day's Range | 3.5200 - 3.7100 |
| 52 Week Range | 2.8000 - 9.9500 |
| Volume | 1,036,378 |
| Avg. Volume | 2,080,334 |
| Market Cap | 397.127M |
| Beta (3Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0040 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.93 |
- Insider Monkey•7 days ago
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has experienced […]
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT
Q1 2019 BioCryst Pharmaceuticals Inc Earnings Call
- GlobeNewswire•15 days ago
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees options to purchase an aggregate of 67,500 shares of BioCryst common stock on May 31, 2019, as inducements material to each employee entering into employment with BioCryst. The options have an exercise price of $3.50 per share, which is equal to the closing price of BioCryst common stock on the grant date. Each stock option vests in four equal annual installments beginning on the one-year anniversary of its grant date, in each case, subject to the new employee’s continued service with the company.
- GlobeNewswire•19 days ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 31, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare.
- Motley Fool•20 days ago
Here's Why BioCryst Pharmaceuticals Is Soaring Today
A hedge fund disclosed a sizable stake in the company.
- Benzinga•28 days ago
The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
- Motley Fool•29 days ago
Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
Tough conditions for these companies left them out of the day's rally.
- American City Business Journals•29 days ago
In less than six hours today, this Durham company's stock has dropped 50 percent
One Triangle drug-maker is feeling confident following a successful Phase III trial – despite some less confident investors pulling the stock down nearly 50 percent.
- Motley Fool•29 days ago
Here's Why BioCryst Pharmaceuticals Collapsed Today
This is a case study of when a successful phase 3 trial isn't successful enough.
- Benzinga•29 days ago
BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial
BioCryst announced Tuesday that a Phase 3 study dubbed APeX-2, which is evaluating once-daily, oral BCX7353 — a selective inhibitor of plasma kallikrein — in preventing hereditary angioedema, or HAE, attacks, met the primary endpoint for both the 110mg and 150mg dose levels. The primary efficacy endpoint is the rate of investigator-confirmed angioedema attacks over 24 weeks of study drug administration. The 110mg dose of BCX7353 reduced the HAE attack rate by 30 percent compared to placebo and the 150mg dose reduced the attack rate by 44 percent.
- GlobeNewswire•29 days ago
BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
Fifty percent of patients receiving 150 mg BCX7353 in APeX-2 had a ≥ 70 percent reduction in their HAE attack rate compared to baseline, compared to 15 percent of placebo patients (p=0.002). In patients on the 150 mg dose with a baseline attack rate of
- Zacks•last month
Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
- GlobeNewswire•last month
BioCryst to Present at Bank of America Merrill Lynch Health Care Conference
RESEARCH TRIANGLE PARK, N.C., May 10, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch.
- GlobeNewswire•last month
BioCryst Completes Phase 1 Clinical Trial of Galidesivir
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. In the trial, galidesivir was generally safe and well tolerated. This placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in four single-dose cohorts of 5mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg, with a total of 24 volunteers receiving galidesivir by IV infusion. Drug exposures (Cmax and AUC) at the highest dose were 20,500 ng/mL and 44,600 hr.ng/mL, similar to or greater than drug exposures needed in nonclinical galidesivir treatment experiments in Marburg virus disease and Yellow Fever.
Motley Fool•last monthBiocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2019.
- Zacks•last month
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
BioCryst: 1Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
BioCryst Reports First Quarter 2019 Financial Results
—Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial.
- GlobeNewswire•last month
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 141,224 shares of BioCryst common stock on April 30, 2019 and May 1, 2019, respectively, as inducements material to each employee entering into employment with BioCryst. The options have an exercise price of $7.43 and $7.28 per share, which is equal to the closing price of BioCryst common stock on each grant date. Each stock option vests in four equal annual installments beginning on the one-year anniversary of its grant date, in each case, subject to the new employee’s continued service with the company.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX)
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
- Zacks•2 months ago
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
BioCryst to Report First Quarter 2019 Financial Results on May 8
RESEARCH TRIANGLE PARK, N.C., April 24, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial.
- Zacks•2 months ago
Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
